Trius initiated is conducting a phase III trial of tedizolid, an oxazolidinone antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA).
Attributes | Values |
---|---|
rdfs:label |
|
rdfs:comment |
|
sameAs | |
dbkwik:speedydelet...iPageUsesTemplate |
|
concern |
|
Timestamp |
|
abstract |
|